A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
Plain-language summary
This trial is testing CAR-T cell therapy (genetically modified immune cells) for patients with angioimmunoblastic T-cell lymphoma (AITL) or TFH lymphomas, anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphoma (CTCL), enteropathy-associated T-cell lymphoma, hepatosplenic T-cell lymphoma, or subcutaneous panniculitis-like T-cell lymphoma whose disease has come back or stopped responding to prior treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. Patients are randomly assigned to different treatment groups. This trial is available at 1 location in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years to 120 Years years
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Cyclophosphamide (DRUG): Days -5 to -3: Cyclophosphamide 300 mg/m\^2 x 3 days | Fludarabine (DRUG): Days -5 to -3: Fludarabine 30 mg/m\^2 IV daily over 30 minutes for 3 days | Autologous CCR4 CAR T cells (BIOLOGICAL): Day 0: Cells will be infused intravenously (IV) over 10-30 minutes
Cyclophosphamide, Fludarabine, Autologous CCR4 CAR T cells
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details